Ovid Therapeutics Inc., a biopharmaceutical company focused on brain conditions with unmet needs, will host an investor and media event on Thursday, June 12, 2025. The event will center on the application of biomarkers in epilepsy, specifically showcasing the pharmacodynamic activity of their OV329 clinical development program. This program involves a next-generation GABA-aminotransferase inhibitor aimed at providing a novel approach for treatment-resistant seizures. The event will feature insights from Dr. Alexander Rotenberger and will be available via a live webcast.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.